Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
A shareholder has filed a notice of intent to sell common stock under Rule 144. The filing covers the planned sale of 2,064 common shares through Fidelity Brokerage Services LLC on or about 01/22/2026, to be traded on NASDAQ at an aggregate market value of $44,923.79.
The 2,064 shares were acquired on 01/21/2026 via restricted stock vesting from the issuer as compensation. The notice also lists prior sales by James G. Chopas over the past three months, including 873 common shares sold on 01/13/2026 for $19,369.43 and 726 common shares sold on 01/20/2026 for $14,369.65.
A Form 144 notice indicates that Caroline R. Baumal plans to sell up to 2,797 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $60,877.82. These shares relate to restricted stock that vested on 01/21/2026 and were acquired from the issuer as compensation.
The planned sale is expected to occur around 01/22/2026 on the NASDAQ, and the filing notes that 126,525,218 shares of this class were outstanding. In the prior three months, Baumal sold additional common shares in two transactions totaling 4,902 shares, for gross proceeds of $77,096.67 and $37,250.24, respectively. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine share sale related to tax withholding. On January 20, 2026, she sold 1,882 shares of Apellis common stock at a price of $19.7929 per share. According to the footnote, this sale was made to cover tax withholding on Restricted Stock Units that were released on January 16, 2026.
After this transaction, Baumal beneficially owned 89,324 shares of Apellis common stock in direct ownership form. The filing indicates this was a single non-derivative transaction coded as a sale, tied specifically to the vesting of equity compensation rather than an open-market discretionary sale.
Apellis Pharmaceuticals VP/Chief Accounting Officer James George Chopas reported a small sale of company stock in connection with equity compensation. On January 20, 2026, he sold 726 shares of Apellis common stock at a price of $19.7929 per share. According to the filing, these shares were sold to cover tax withholding on restricted stock units that were released on January 16, 2026.
After this transaction, Chopas beneficially owned 51,869 shares of Apellis common stock in direct ownership. The filing indicates the transaction was a routine tax-related sale rather than an open-market discretionary reduction of his overall stake.
Apellis Pharmaceuticals Chief Business & Strat Officer Mark Jeffrey DeLong reported a small stock sale related to tax withholding. On January 20, 2026, he sold 1,334 shares of Apellis common stock at an average price of $19.7929 per share, coded as a sale transaction.
According to the filing, this sale represents shares sold to cover tax withholding on restricted stock units that were released on January 16, 2026. After this transaction, DeLong directly owns 81,724 shares of Apellis common stock.
Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a small share sale related to tax withholding. On January 20, 2026, he sold 909 shares of Apellis common stock at an average price of $19.7929 per share. The filing explains that these shares were sold to cover taxes due on Restricted Stock Units that vested on January 16, 2026.
After this transaction, Deschatelets beneficially owned 1,157,310 shares of Apellis common stock in direct form. The transaction is reported on a Form 4 as a non-derivative disposition coded "S," indicating an open-market or similar sale.
Apellis Pharmaceuticals, Inc. Chief Executive Officer and director Cedric Francois reported a sale of common stock mainly tied to taxes on equity compensation. On January 20, 2026, he sold 8,182 shares of Apellis common stock at $19.7929 per share, in a transaction described as covering tax withholding on restricted stock units that were released on January 16, 2026. Following this sale, he directly owned 313,237 shares of common stock.
In addition to his direct holdings, the filing lists several indirect holdings through trusts, including 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. The filing states that Francois disclaims beneficial ownership of shares held in these trusts except to the extent of his pecuniary interest.
Apellis Pharmaceuticals, Inc. insider transaction: Chief Technical Officer Nicholson Nur reported a sale of 2,203 shares of Apellis common stock on January 20, 2026, at a price of $19.7929 per share. According to the footnote, these shares were sold to cover tax withholding related to Restricted Stock Units that were released on January 16, 2026, rather than as an open-market discretionary sale. After this transaction, Nur beneficially owned 78,843 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported a small sale of company stock primarily to cover taxes from equity compensation. On January 20, 2026, he sold 2,892 shares of common stock at an average price of $19.7929 per share, described as shares sold to cover tax withholding on restricted stock units that were released on January 16, 2026. After this transaction, he directly held 104,188 shares of Apellis common stock. In addition, 60,396 shares are held indirectly by The Timothy E Sullivan Irrevocable Trust of 2023, for which a separate trustee, Patrick O. Collins, acts, and over which Sullivan disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals’ general counsel, David O. Watson, reported selling 2,475 shares of common stock on January 20, 2026 at $19.7929 per share. According to the filing, these shares were sold to cover tax withholding on restricted stock units that were released on January 16, 2026.
After this transaction, Watson beneficially owned 96,363 common shares directly. He also reported indirect holdings, including 10,000 shares in a custodial account for the sole benefit of his minor children, and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except for any pecuniary interest. The Watson Education Trust reported holding no shares following the reported transactions, with similar beneficial ownership disclaimers.